Dr. Luis Ostrosky, professor of infectious disease at McGovern Medical School at UTHealth, co-investigator of first Texas randomized trial in hospitalized patients for convalescent therapy for COVID-19, is available to discuss latest data and FDA's hold on the emergency authorization of blood plasma treatment.

MEDIA CONTACT
Register for reporter access to contact details
RELATED EXPERTS
TYPE OF ARTICLE
Expert Pitch
SECTION
CHANNELS
Blood Clinical Trials Government and Law Infectious Diseases Public Health Coronavirus
KEYWORDS
COVID-19 blood plasma Convalescent Plasma Mayo FDA COVID-19 Texas
COMMENTS | COMMENTING POLICY